Raynaud's phenomenon.

[1]  J. Marshall,et al.  Lack of habituation of the pattern of cardiovascular response evoked by sound in subjects with primary Raynaud's disease , 1998 .

[2]  R. Madhok,et al.  Oral iloprost as a treatment for Raynaud's syndrome: a double blind multicentre placebo controlled study. , 1995, Annals of the rheumatic diseases.

[3]  L. Kaufman,et al.  Intravenous Iloprost Infusion in Patients with Raynaud Phenomenon Secondary to Systemic Sclerosis: A Multicenter, Placebo-controlled, Double-Blind Study , 1994, Annals of Internal Medicine.

[4]  C. Lau,et al.  White blood cell activation in Raynaud's phenomenon of systemic sclerosis and vibration induced white finger syndrome. , 1992, Annals of the rheumatic diseases.

[5]  J. Belch.  Raynaud's phenomenon , 1991, Current opinion in rheumatology.

[6]  J. Belch,et al.  Raynaud's phenomenon: its relevance to scleroderma. , 1991, Annals of the rheumatic diseases.

[7]  W. F. Blair,et al.  Digital Periarterial Sympathectomy for Ischaemic Digital Pain and Ulcers , 1991, Journal of hand surgery.

[8]  B. Hazleman,et al.  Prolonged effect of CGRP in Raynaud's patients: a double-blind randomised comparison with prostacyclin. , 1991, British journal of clinical pharmacology.

[9]  M. Mayes,et al.  Plasma catecholamines during behavioral treatments for Raynaud's disease. , 1991, Psychosomatic medicine.

[10]  C. Bunker,et al.  Deficiency of calcitonin gene-related peptide in Raynaud's phenomenon , 1990, The Lancet.

[11]  M. Zamora,et al.  Serum endothelin-1 concentrations and cold provocation in primary Raynaud's phenomenon , 1990, The Lancet.

[12]  M. Goodfield,et al.  The acute effects of cigarette smoking on cutaneous blood flow in smoking and non-smoking subjects with and without Raynaud's phenomenon. , 1990, British journal of rheumatology.

[13]  J. D. Coffman.  The enigma of primary Raynaud's disease. , 1989, Circulation.

[14]  M. Weinrich,et al.  Prevalence of scleroderma spectrum disorders in the general population of South Carolina. , 1989, Arthritis and rheumatism.

[15]  M. Greaves,et al.  Prostacyclin production by human umbilical vein endothelium in response to serum from patients with systemic sclerosis. , 1989, British journal of rheumatology.

[16]  J. Kirby,et al.  Comparison of intravenous infusions of iloprost and oral nifedipine in treatment of Raynaud's phenomenon in patients with systemic sclerosis: a double blind randomised study. , 1989, BMJ.

[17]  J. Belch,et al.  Decreased oesophageal blood flow in patients with Raynaud's phenomenon. , 1988, British journal of rheumatology.

[18]  Porter Jm,et al.  Late-onset Raynaud's syndrome: diagnostic and therapeutic considerations. , 1988 .

[19]  M. Kahaleh,et al.  Effect of lymphotoxin and tumor necrosis factor on endothelial and connective tissue cell growth and function. , 1988, Clinical immunology and immunopathology.

[20]  C. Kallenberg,et al.  Development of connective tissue disease in patients presenting with Raynaud's phenomenon: a six year follow up with emphasis on the predictive value of antinuclear antibodies as detected by immunoblotting. , 1988, Annals of the rheumatic diseases.

[21]  J. Faber.  Effect of local tissue cooling on microvascular smooth muscle and postjunctional alpha 2-adrenoceptors. , 1988, The American journal of physiology.

[22]  E. Hess,et al.  Prospective study of the evolution of Raynaud's phenomenon. , 1988, The American journal of medicine.

[23]  M. Molaschi,et al.  Functional Vascular Disorders: Treatment with Pentoxifylline , 1987, Angiology.

[24]  C. Forbes,et al.  Abnormal Biochemical and Cellular Parameters in the Blood of Patients with Raynauds Phenomenon , 1987, Scottish medical journal.

[25]  B. Amor,et al.  Nifedipine and thallium-201 myocardial perfusion in progressive systemic sclerosis. , 1986, The New England journal of medicine.

[26]  A. Willan,et al.  A double blind placebo controlled crossover randomized trial of diltiazem in Raynaud's phenomenon. , 1985, The Journal of rheumatology.

[27]  V. C. Roberts,et al.  Reflex vascular responses in the finger to contralateral thermal stimuli during the normal menstrual cycle: a hormonal basis to Raynaud's phenomenon? , 1985, Clinical science.

[28]  M. Urowitz,et al.  67Gallium lung scans in progressive systemic sclerosis. , 1983, Arthritis and rheumatism.

[29]  C. Forbes,et al.  INTERMITTENT EPOPROSTENOL (PROSTACYCLIN) INFUSION IN PATIENTS WITH RAYNAUD'S SYNDROME A Double-blind Controlled Trial , 1983, The Lancet.

[30]  E. Kinney,et al.  Plasma 6 keto PGF1α concentration in Raynaud's phenomenon , 1981 .

[31]  J. Porter,et al.  Evaluation and management of patients with Raynaud's syndrome. , 1981, American journal of surgery.

[32]  T. The,et al.  Systemic involvement and immunologic findings in patients presenting with Raynaud's phenomenon. , 1980, The American journal of medicine.

[33]  K. H. Nilsen.  Effects of naftidrofuryl on microcirculatory cold sensitivity in Raynaud's phenomenon. , 1979, British medical journal.

[34]  D. James,et al.  Kielland's forceps: role of antenatal factors in prediction of use. , 1979, British medical journal.

[35]  J. Rösch,et al.  The clinical significance of Raynaud's syndrome. , 1976, Surgery.

[36]  Peacock Jh.  Vasodilatation in the human hand; observations on primary Raynaud's disease and acrocyanosis of the upper extremities. , 1958 .

[37]  C. Forbes,et al.  Vascular damage and factor-VIII-related antigen in the rheumatic diseases , 1987, Thrombosis and Haemostasis.

[38]  M. Weinrich,et al.  Prevalence of Raynaud phenomenon in the general population. A preliminary study by questionnaire. , 1986, Journal of chronic diseases.